Nano-Based Drug Delivery Systems of Potent MmpL3 Inhibitors for Tuberculosis Treatment
Tuberculosis remains one of the world's deadliest infectious diseases, accounting for nearly 1.3 million deaths every year. Tuberculosis treatment is challenging because of the toxicity, decreased bioavailability at the target site of the conventional drugs and, most importantly, low adherence...
Saved in:
Main Authors: | Patrizia Nadia Hanieh (Author), Sara Consalvi (Author), Jacopo Forte (Author), Gianluigi Cabiddu (Author), Alessandro De Logu (Author), Giovanna Poce (Author), Federica Rinaldi (Author), Mariangela Biava (Author), Maria Carafa (Author), Carlotta Marianecci (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Rifampicin-Liposomes for <i>Mycobacterium abscessus</i> Infection Treatment: Intracellular Uptake and Antibacterial Activity Evaluation
by: Federica Rinaldi, et al.
Published: (2021) -
Deciphering the possible role of MmpL7 efflux pump in SQ109 resistance in Mycobacterium tuberculosis
by: Wei Jing, et al.
Published: (2024) -
N-isopropyl-(4-methoxy-3-difluoromethyl)cinnamoyl amide targets mycobacterial MmpL3
by: Mario D. Martínez, et al.
Published: (2024) -
SAR Analysis of Small Molecules Interfering with Energy-Metabolism in <i>Mycobacterium tuberculosis</i>
by: Federico Appetecchia, et al.
Published: (2020) -
Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances
by: Chiara Tammaro, et al.
Published: (2023)